JPMorgan Chase & Co. Raises Stock Position in Beta Bionics, Inc. $BBNX

JPMorgan Chase & Co. increased its position in shares of Beta Bionics, Inc. (NASDAQ:BBNX) by 3,238.0% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 205,955 shares of the company’s stock after acquiring an additional 199,785 shares during the period. JPMorgan Chase & Co. owned approximately 0.47% of Beta Bionics worth $4,092,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of BBNX. GPS Wealth Strategies Group LLC grew its position in shares of Beta Bionics by 45.0% during the 3rd quarter. GPS Wealth Strategies Group LLC now owns 1,450 shares of the company’s stock valued at $29,000 after purchasing an additional 450 shares in the last quarter. Strs Ohio bought a new position in shares of Beta Bionics in the first quarter worth $29,000. EverSource Wealth Advisors LLC boosted its stake in Beta Bionics by 203.6% during the third quarter. EverSource Wealth Advisors LLC now owns 2,377 shares of the company’s stock valued at $47,000 after buying an additional 1,594 shares during the period. Legal & General Group Plc boosted its stake in Beta Bionics by 197.4% during the second quarter. Legal & General Group Plc now owns 3,976 shares of the company’s stock valued at $58,000 after buying an additional 2,639 shares during the period. Finally, Ameritas Investment Partners Inc. grew its position in Beta Bionics by 139.1% during the third quarter. Ameritas Investment Partners Inc. now owns 3,202 shares of the company’s stock worth $64,000 after buying an additional 1,863 shares in the last quarter.

Analyst Ratings Changes

A number of equities analysts have weighed in on BBNX shares. Stifel Nicolaus decreased their target price on Beta Bionics from $25.00 to $22.00 and set a “buy” rating on the stock in a research note on Wednesday, February 18th. Lake Street Capital set a $20.00 price objective on Beta Bionics in a report on Wednesday, February 18th. Wall Street Zen cut shares of Beta Bionics from a “hold” rating to a “sell” rating in a research report on Sunday, March 29th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Beta Bionics in a research note on Friday, March 27th. Finally, UBS Group upgraded shares of Beta Bionics to a “strong-buy” rating in a research report on Monday, February 9th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Beta Bionics has a consensus rating of “Moderate Buy” and an average target price of $23.20.

Beta Bionics Price Performance

NASDAQ BBNX opened at $9.93 on Friday. The stock’s 50-day simple moving average is $12.33 and its two-hundred day simple moving average is $20.89. Beta Bionics, Inc. has a twelve month low of $8.89 and a twelve month high of $32.71. The company has a market capitalization of $440.69 million, a price-to-earnings ratio of -5.09 and a beta of 5.06.

Beta Bionics (NASDAQ:BBNX) last posted its quarterly earnings data on Tuesday, February 17th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.12. The firm had revenue of $32.12 million during the quarter. Beta Bionics had a negative return on equity of 20.29% and a negative net margin of 73.02%.

Insiders Place Their Bets

In other Beta Bionics news, insider Mike Mensinger sold 2,200 shares of the company’s stock in a transaction that occurred on Tuesday, January 6th. The stock was sold at an average price of $30.10, for a total value of $66,220.00. Following the completion of the sale, the insider owned 80,752 shares of the company’s stock, valued at $2,430,635.20. This represents a 2.65% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In the last ninety days, insiders sold 6,905 shares of company stock valued at $124,095.

Beta Bionics Company Profile

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.